[The prognostic significance of brain-derived neurotrophic factor (BDNF) for phobic anxiety disorders, vegetative and cognitive impairments during conservative treatment including adaptol of some functional and organic diseases of nervous system].
We have studied the efficacy of adaptol in the treatment of 45 patients with somatoform dysfunction of the autonomic nervous system and 30 patients with closed head injury. The condition of patients during the treatment was evaluated with clinical and neuropsychological scales. The serum level of BDNF before and after the treatment has been studied as well. Adaptol has been shown to enhance the production of BDNF, reduce significantly the intensity of anxiety, autonomic disorders and improve intellectual processes. The dose-dependent effect of the drug has been demonstrated. In conclusion, adaptol can be recommended for treatment of diseases that demand stimulation of neuroplasticity in the CNS.
S A
SA
Zhivolupov
I N
IN
Samartsev
A A
AA
Marchenko
O V
OV
Puliatkina
D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000097:blood / Q000188:drug therapy*; D001342:Autonomic Nervous System Diseases / Q000097:blood / Q000188:drug therapy*; D001736:Biureas / Q000008:administration & dosage / Q000627:therapeutic use*; D019208:Brain-Derived Neurotrophic Factor / Q000097:blood*; D003072:Cognition Disorders / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008875:Middle Aged; D010698:Phobic Disorders / Q000097:blood / Q000188:drug therapy*; D011379:Prognosis; D016896:Treatment Outcome; D055815:Young Adult
D014151:Anti-Anxiety Agents; D001736:Biureas; D019208:Brain-Derived Neurotrophic Factor; C015979:mebikar